The immune system plays a major role in melanoma outcomes.5,6 For example, immune checkpoint inhibition (ICI) as cancer immunotherapy has shown remarkable efficacy in improving T cell responses and prolonging survival in melanoma patients.7 ICI currently consists of antibodies blocking the IC PD-1, PD-L1, or CTLA-4, all of which are approved to treat melanoma. This evidence concerns the gene CTLA4 and melanoma.